Umbralisib
- TRADE NAME: Ukoniq (TG Therapeutics)
- INDICATIONS:
Relapsed or refractory marginal zone lymphoma (subsequent to an anti-CD20-based regimen)
Relapsed or refractory follicular lymphoma (following previous systemic therapy)
- CLASS: Kinase inhibitor, Phosphoinositide 3-kinase (Phosphatidylinositol 3-kinase) (PI3K) inhibitor
- HALF-LIFE: 91 hours
FDA APPROVAL DATE: 02/05/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
May cause fetal harm when administered to a pregnant woman. Advise use of contraceptives.
Please login to see the rest of this drug profile
SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 01/31/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric